Biotech Startups

HelloBiome runs independent Clinical Claims Studies that measure a product's impact on the human microbiome and awards a Microbiome Seal to products meeting its validation criteria. It serves consumer brands in skincare, haircare, oral, intimate, and body categories, providing third-party clinical validation and claims-ready reporting.

1 investor

Predictive Oncology (POAI) operates an AI/ML platform powered by a biobank of over 150,000 tumor samples across 137 cancer types to predict tumor-drug response for oncology drug discovery. It serves pharmaceutical drug developers, offering drug-response predictions, drug repurposing, and pre-clinical tumor heterogeneity modeling.

1 investor

Helsinn is a global pharmaceutical company that develops and distributes supportive care medications for patients with cancer and chronic diseases. The company operates through a combination of direct sales in the United States and commercial partnerships internationally.

1 investor

Hemerion develops photonic drug-device combination therapies for treating glioblastomas and other brain tumors in clinical settings. The company combines photosensitizing drugs with innovative photonic systems designed to integrate into surgical workflows and selectively destroy tumor cells.

1 investor

Hemispherian is a clinical-stage pharmaceutical company developing small molecule drugs that target the TET2 enzyme as targeted therapies for aggressive cancers. Its lead compound GLIX1 is entering clinical development for glioblastoma, a cancer of the central nervous system.

1 investor

Hemo Group develops interventional medical devices for treating neuro-vascular diseases, including ischemic stroke, hemorrhagic stroke, and neuro access, with products such as the Afentta intracranial thrombectomy device. The company markets its devices across Europe, Asia, and the Middle East, with R&D conducted in the US.

1 investor

Hemostemix is a clinical-stage regenerative medicine company developing ACP-01, an investigational autologous (patient-derived) stem cell therapy for vascular and ischemic conditions such as critical limb ischemia, peripheral arterial disease, ischemic cardiomyopathy, and heart failure. The company runs Phase I and Phase II clinical programs and is publicly traded (TSXV: HEM | OTCQB: HMTXF).

1 investor

HemostOD engineers and manufactures universal (HLA-low) platelets using a proprietary platform that immortalizes hematopoietic progenitor cells and generates platelets via microfluidic bioreactors. The preclinical biotech targets applications in thrombocytopenia, tissue-targeted cargo delivery, regenerative medicine, and therapeutic stem cell culture.

1 investor

hemotune develops a magnetic nanoparticle platform for targeted magnetic separation in medical and biomanufacturing applications. The platform removes disease triggers and harmful agents from the bloodstream or processes biological materials with high selectivity and scalability.

1 investor

Henlez is an early-stage biotech company working in the dermatology space.

1 investor

HepQuant develops noninvasive, blood-based quantitative tests that measure liver cell function and blood flow to assess liver health and disease severity. The tests are used by healthcare providers to manage patients with advanced liver disease and by drug developers in clinical trials.

1 investor

Heqet Therapeutics is a pre-clinical stage biotech developing non-coding RNA-based therapies for cardiovascular diseases, with a focus on acute myocardial infarction. Its compounds target multiple pathways through the upregulation of certain non-coding RNAs to promote heart regeneration.

1 investor

Hera BioLabs provides gene editing technologies and cell line development services for drug discovery researchers. The company offers custom cell line platforms, animal models, and bioprocessing solutions using transposase technology and proprietary tools like the SRG Rat platform and CleanCut GS CHO system.

1 investor

Herikîn develops automation platforms for biomanufacturing, focusing on simplified RNA production and processing. The company serves research labs and bioproduction facilities seeking scalable, accessible tools for biological molecule manufacturing.

1 investor

Hermes Biosciences develops a benchtop system for isolating extracellular vesicles and exosomes from bodily fluids and cell culture media for research and clinical applications in oncology, degenerative disease, and regenerative medicine.

1 investor

Hesperos develops "Human-on-a-Chip" organ-on-a-chip platforms, offering custom multi-organ models (up to 5 organ or tissue types) with functional readouts such as gene expression and electrophysiology. The systems provide pre-clinical efficacy and toxicity data on drugs and chemicals for the pharmaceutical, cosmetic, and food industries.

1 investor

HGS BioScience produces liquid and powder agricultural products containing extracted humates to improve nutrient uptake and crop yield for farmers. The company offers formulations with fulvic and humic acids, sea plant extracts, and kelp-based solutions designed to enhance plant stress tolerance and performance throughout the growing season.

1 investor

HHC Medical develops wireless electroporation technology based on an established biophysical phenomenon, aimed at improving treatment safety and enabling delivery of diverse payloads. The company works in the medical device and biotech space.

1 investor

PACT develops earth-positive bio-based materials for fashion and consumer brands, focusing on scalable, sustainable alternatives to conventional materials. The company operates a research and development laboratory and pilot manufacturing facilities to scale up its biomaterials for partner brands.

1 investor

Hifas da Terra is a biotechnology company that develops mushroom-based natural health supplements, including products for stress, sleep, digestive health, menopause, and vitamin D. It sells directly to consumers and works with health professionals, positioning itself in the nutraceutical and wellness market.

1 investor

High Q Technologies builds quantum-enabled scientific instruments that apply microwave quantum optics techniques to electron paramagnetic resonance (EPR) spectroscopy for ultra-high sensitivity biophysical and chemical analysis. Its technology targets protein structure determination and drug discovery, serving researchers and pharmaceutical development.

1 investor

HighCape Partners is a venture capital firm investing in connected health, medical devices, and biotechnology companies. The firm provides capital and operational expertise to early-stage and growth-stage life sciences companies.

1 investor

H.I.G. HealthBridge Capital Partners is a growth equity investment fund focused on healthcare companies across medical devices, biopharmaceuticals, digital health, diagnostics, and related services.

1 investor

Higher Steaks uses cell culture techniques to grow meat products from animal cell samples without traditional animal farming. The company serves food producers and consumers seeking cultivated meat alternatives.

1 investor